Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study

J Comp Eff Res. 2023 Apr;12(4):e220181. doi: 10.57264/cer-2022-0181. Epub 2023 Mar 8.

Abstract

Aim: This online interactive survey investigated lipid-lowering approaches of French cardiologists in high- and very high-cardiovascular risk patients with hypercholesterolemia. Materials & methods: Physicians assessed three hypothetical patients at three clinic visits, and selected the patients' cardiovascular risk category, target low-density lipoprotein cholesterol (LDL-C) and treatment. Results: A total of 162 physicians completed 480 risk assessments; 58% of assessments correctly categorized the hypothetical patients. Most physicians chose the correct LDL-C target for one of the very high-risk patients, but higher-than-recommended targets were selected for the other very high-risk patient and the high-risk patient. Statins were the most commonly chosen treatment. Conclusion: French cardiologists often underestimate cardiovascular risk in patients with hypercholesterolemia, select a higher-than-recommended LDL-C target and prescribe less intensive treatment than that recommended by guidelines.

Keywords: France; cardiologists; cardiovascular risk; case-vignette; ezetimibe; hypercholesterolemia; lipid-lowering; online interactive survey; statin; treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents* / therapeutic use
  • Cardiologists*
  • Cholesterol, LDL
  • France
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hypercholesterolemia* / complications
  • Hypercholesterolemia* / drug therapy

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Anticholesteremic Agents